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Abstract
Background: Presence of circulating tumor cells (CTCs) is a validated prognostic marker in metastatic breast cancer.
Additional prognostic information may be obtained by morphologic characterization of CTCs. We explored whether
apoptotic CTCs, CTC clusters and leukocytes attached to CTCs are associated with breast cancer subtype and
prognosis at base-line (BL) and in follow-up (FU) blood samples in patients with metastatic breast cancer scheduled
for first-line systemic treatment.
Methods: Patients with a first metastatic breast cancer event were enrolled in a prospective observational study
prior to therapy initiation and the CellSearch system (Janssen Diagnostics) was used for CTC enumeration and
characterization. We enrolled patients (N = 52) with ≥5 CTC/7.5 ml blood at BL (median 45, range 5–668) and
followed them with blood sampling for 6 months during therapy. CTCs were evaluated for apoptotic changes, CTC
clusters (≥3 nuclei), and leukocytes associated with CTC (WBC-CTC, ≥1 CTC + ≥1 leukocytes) at all time-points by
visual examination of the galleries generated by the CellTracks Analyzer.
Results: At BL, patients with triple-negative and HER2-positive breast cancer had blood CTC clusters present more
frequently than patients with hormone receptor-positive cancer (P = 0.010). No morphologic characteristics were
associated with prognosis at BL, whereas patients with apoptotic CTCs or clusters in FU samples had worse
prognosis compared to patients without these characteristics with respect to progression-free (PFS) and overall
survival (OS) (log-rank test: P = 0.0012 or lower). Patients with apoptotic or clustered CTCs at any time-point had
impaired prognosis in multivariable analyses adjusting for number of CTCs and other prognostic factors (apoptosis:
HROS = 25, P < 0.001; cluster: HROS = 7.0, P = 0.006). The presence of WBC-CTCs was significantly associated with an
inferior prognosis in terms of OS at 6 months in multivariable analysis.
Conclusions: Patients with a continuous presence of apoptotic or clustered CTCs in FU samples after systemic
therapy initiation had worse prognosis than patients without these CTC characteristics. In patients with ≥5 CTC/7.5
ml blood at BL, morphologic characterization of persistent CTCs could be an important prognostic marker during
treatment, in addition to CTC enumeration alone.
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Background
Hematogenous spread of cancer cells and subsequent
formation of metastases in distant organs is the leading
cause of death in cancer patients. A key step in metastasis
is intravasation, i.e. the entrance of tumor cells into the
hematologic or lymphatic system. Carcinoma-derived
tumor cells circulating in the bloodstream, or circulating
tumor cells (CTCs), in metastatic breast [1], prostate [2],
colorectal [3], and lung [4, 5] cancer are associated with
decreased progression-free survival (PFS) and overall sur-
vival (OS), and serial sampling after therapy initiation has
also shown a prognostic importance of longitudinal CTC
enumeration in metastatic breast cancer [1, 6–9].
Enumeration of CTCs in a liquid biopsy is a non-
invasive monitoring that is easy to obtain via a periph-
eral blood sample and may hold promise for improving
cancer prognostication and treatment. The most com-
monly used enrichment and detection technique for
CTCs is the FDA approved CellSearch system (Janssen
Diagnostics LLC, Raritan, NJ, USA). Molecular studies
of CTCs are accumulating but few studies have thus
far described morphological characteristics of CTCs,
using either CellSearch-derived CTCs [10–14] or
other methods for CTC isolation [15–20].
The malignant potential of CTCs has been suggested
to be reflected in their morphological characteristics and
these attributes are thus starting to be evaluated in clin-
ical studies and related to outcome. A high fraction of
apoptotic CTCs in the blood or apoptotic disseminated
tumor cells (DTCs) in the bone-marrow in patients with
solid tumors have been reported to be associated with
decreased PFS and/or OS [4, 21–24]. The presence of
CTC clusters has been reported for patients with meta-
static colorectal, renal, prostate, lung and breast cancer
[4, 12, 25–29] and the presence of clusters has been cor-
related to decreased survival in a few studies in small-
cell lung cancer [4] and breast cancer [12, 14]. Diagnosis
of CTC clusters (defined as ≥2 CTCs) have been related
to poor outcome in stage III-IV breast cancer using
the CellSearch system for CTC enumeration and
characterization [14]. Paoletti et al [12] defined CTC
clusters as ≥3 CTCs in the CellSearch gallery and for
definition of apoptotic CTCs they applied M-30 stain-
ing as well as morphologic evaluation. They reported
on prognostic information obtained by diagnosis of
CTC clusters and apoptosis in metastatic triple-
negative breast cancer showing that CTC clusters, but
not apoptotic CTCs, added prognostic information in FU
samples [12]. To date no consensus has been reached
regarding the definitions of these morphologic character-
istics using the CellSearch system and if additional bio-
markers for diagnosis of apoptosis are needed.
Mixed clusters comprised of CTCs and leukocytes/
white blood cells (WBC-CTC) have not been thoroughly
investigated, but the complex relationship between CTCs
and the immune system is gaining attention [30]. Gener-
ally, interactions between CTCs and the tumor micro-
environment are still poorly understood but previous
results have shown that specific immune cells have
immunosuppressive properties in the peripheral blood,
while this effect is absent in these cells in a tumor-
associated environment [31, 32]. Also, association of
CTCs with lymphocytes and platelets has been sug-
gested to protect tumor cells against natural-killer
(NK) cell-mediated lysis [33, 34].
We hypothesized that CTC clusters and apoptosis in
metastatic breast cancer can provide prognostic infor-
mation along CTC enumeration in all breast cancer sub-
types and we sought to morphologically characterize
CTCs in serial blood samples from patients with high
risk (≥5 CTCs at base-line (BL)) metastatic breast can-
cer. All included patients were recently diagnosed with a
first metastatic event and about to start first-line therapy
in the metastatic setting. We explored whether apop-
tosis, CTC clusters and WBC-CTCs identified after
CellSearch analysis without further staining were related
to disease progression and survival, and if morphologic
CTC characteristics differ among breast cancer subtypes
and during follow-up (FU) from BL to 6 months after
first-line systemic therapy. The present study shows that
diagnosis of CTC clusters before start of systemic
therapy correlate with an aggressive phenotype (triple-
negative and HER2-subtype) and that presence of CTC
clusters and apoptotic CTCs add prognostic information
in FU samples even when adjusting for other prognostic
factors.
Methods
Patients and study design
An ongoing prospective monitoring trial at the
Department of Oncology and Pathology, Lund University,
Sweden aims to quantify and characterize CTCs in pa-
tients with metastatic breast cancer using progression-free
survival (PFS) as a primary end-point. Women with
distant metastases at diagnosis or first relapse meta-
static breast cancer scheduled for first-line systemic
treatment for metastatic disease in Lund, Malmö and
Halmstad, have been included from 2011 (Clinical Trials
NCT01322893) after oral and written informed consent
(including publication of patient’s data). The study was
approved by the Ethics committee at Lund University,
Lund Sweden (LU 2010/135). Patient blood samples con-
taining ≥5 CTCs at BL between 2011 and 2014 were ana-
lyzed in the present study. Patients were older than 18
years-of-age, with an ECOG performance status of ≤2 and
a predicted life expectancy of >2 months. During the
study, all patients received first-line systemic treatment
for metastatic disease according to national guidelines
Jansson et al. BMC Cancer  (2016) 16:433 Page 2 of 15
(http://www.socialstyrelsen.se/publikationer2014/2014-4-2).
Whole blood was collected from each patient at BL
and after approximately 1, 3, 4, and 6 months of
treatment or until disease progression. In the present
study, we investigated the BL, 1–3 and 6 months
blood samples (see Fig. 1). The 1 month sample was
Fig. 1 Flow-chart of CTC morphology study
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used only for 5 patients who lacked a 3-month sample
(four of these patients were diseased before the scheduled
3-month sample and one sample was missing).
CTC Analysis
CTC detection and evaluation was performed using the
CellSearch system (Janssen Diagnostics LLC, Raritan,
NJ, USA) according to the manufacturer’s instruction.
CellSearch is a semi-automated system that detects and
enriches epithelial cells from whole blood (7.5 ml) using
an epithelial cell adhesion molecule (EpCAM)-antibody
coupled ferrofluid. All cells are counterstained with fluor-
escent antibodies against CD45 and cytokeratins (CK) 8,
18 and 19, and DAPI-stained for nuclear content, before
scanning with a fluorescent microscope (CellTracks
Analyzer II) to present them in a gallery for manual evalu-
ation. CTCs are CK+/CD45-/DAPI+ cells fulfilling certain
predefined criteria [35]. In this study, all gallery events
were independently evaluated by two technicians trained
and certified in the CellSearch technology. Events for
which the assessment differed between the investigators
were re-evaluated and a consensus was reached. Using the
built in export function in the CellTracks Analyzer II sys-
tem the cells selected as CTCs were grouped in a pdf gal-
lery. Cells were subsequently assessed for apoptosis, CTC
clusters and WBC-CTCs by two independent investigators
(KA, SJ). Apoptotic cells were identified as cells with char-
acteristic fragmented and condensed DAPI-stained nu-
clear morphology as defined by a clinical pathologist, and
in the literature [36]. CTC clusters were defined as clus-
ters of CTCs containing ≥3 distinct nuclei according to
previous publications [12, 13]. By this definition it is less
likely to incorrectly assign a mitotic CTC as a cluster. No
additional staining of CTCs after CellSearch analysis was
performed as this study aims to explore the feasibility
of morphologic CTC characterization directly in the
CellSearch gallery. This approach has previously been
suggested in lung cancer [4]. WBC-CTCs were de-
fined as ≥1 CTC clustered with ≥1 leukocyte and no
definitive description of WBC-CTC has been published to
date. Examples of apoptotic CTCs, CTC clusters, and
WBC-CTCs are presented in Fig. 2a-c.
Statistical analysis
Apoptotic CTCs, CTC clusters and WBC-CTCs were di-
chotomized into binary variables as previously described
for CTC clusters [4, 12, 14] and apoptosis [4] and a pa-
tient was considered negative (no apoptotic CTC/CTC-
cluster/WBC-CTC present) or positive (≥1 apoptotic
CTC/CTC-cluster/WBC-CTC present).
Patient, tumor and CTC characteristics across sub-
classes of breast cancers and at different time-points
were compared using a Pearson Chi-squared test or, if
expected counts <5 in one or more of test cells, Fishers
exact test. For ordinal variables with more than two cat-
egories, a linear-by-linear test for association was used
and for variables measured on a continuous scale, the
Mann-Whitney U-test was applied.
The primary end-point was PFS and the secondary
end-point was overall survival (OS), both measured from
BL to disease progression, death, or last FU. Survival
data was retrieved from the patients’ medical charts and
all events until March 2015 were recorded. Survival ana-
lyses of variables measured at 1–3 or 6 months was per-
formed with landmark analysis for which PFS and OS
were calculated from the time of sample taking, e.g. 1–3
or 6 months to disease progression, death, or last FU.
Survival was evaluated using Kaplan-Meier (KM) analysis
and log-rank test. Hazard ratios (HR) were calculated
using Cox regression. Proportional hazards assumptions
were checked graphically and with Schoenfeld’s test. Mul-
tivariable survival analyses were adjusted for the studied
morphological variables, number of CTCs, breast cancer
subgroup, age at diagnosis, time from first breast cancer
diagnosis to diagnosis of metastasis [37], number and site
of metastases. The presence of apoptotic CTCs or CTC
clusters were also analyzed as time-dependent covariates
using Cox regression models by splitting the FU time for
each subject in the study into episodes during which both
covariates were constant.
To account for the proportion of CTCs with the re-
spective morphological characteristic, Cox regression
was also done using the fraction of clustered/apoptotic/
WBC associated CTCs per total number of CTCs in
each patient. Statistical analyses were performed with
IBM SPSS Statistics (version 22.0, IBM, Armonk, NY,
USA) and STATA (version 13.1 StataCorp, (Stata Corp.
College Station, TX, USA).
Results
Patient cohort and breast cancer subgroups
Table 1 offers patient characteristics and the study de-
sign is depicted in Fig. 1. Patients were divided into
three subgroups based on hormone receptor status
(estrogen receptor (ER) and progesterone receptor (PgR))
and HER2 (human epidermal growth factor receptor 2)
status [38]. Breast cancer subtype was primarily derived
from the primary tumor (n = 40) and secondly, if no pri-
mary tumor tissue was available, from metastases (n = 10).
Two patients had insufficient tumor tissue for subtype as-
sessment. The median FU for patients alive at the last re-
view of the patient’s charts was as follows: 12 months
(range 5–44) from BL samples, 10 months (range 1–42)
from 1 to 3 month samples, and 15 months (range 1–38)
from 6 month samples. Median PFS and OS from BL was
10 (95 % CI 9–16) and 19 (95 % CI 14–31) months, re-
spectively. Total number of events until March 2015 in
the cohort was 36 for PFS and 27 for OS.
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CTC counts
Median BL CTC counts did not differ among the three
breast cancer subgroups (P-value = 0.32; Table 2). At 1–
3 months, median CTC counts were greater in patients
with triple-negative breast cancer (P-value = 0.007). This
was not seen at 6 months, but fewer patients at this time
point suggests caution for drawing conclusions from the
results (P-value = 0.18; Table 2 and Fig. 1). Details on
tumor, patient, and CTC characteristics in relation to
breast cancer subgroup can be found in Tables 1 and 2.
Fig. 2 Photos of CTC morphology from CellTracks II Analyzer (10x). The four different columns depict from left to right: Nuclear DAPI staining
(purple)/cytokeratin (CK)-PE (green) overlay, CK-staining, nuclear DAPI staining and CD45-APC staining. Scale bars have been added manually in
each frame. a Examples of apoptotic CTCs from four different patients with characteristic fragmented and condensed apoptotic cell nuclei.
b Examples of CTC clusters (defined as ≥3 nuclei). c Examples of WBC-CTCs
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The established cut-off of ≥5 CTCs was investigated in
survival analyses at 1–3 and 6 months. Data show sig-
nificantly worse PFS and OS at both time-points for pa-
tients with ≥5 CTCs (Table 3 and Additional file 1). OS
analysis at 1–3 months was also repeated without four
patients with data from the 1 month sample due to pa-
tient deaths prior to 3-month sample acquisition and
similar results were obtained. PFS and OS for each
breast cancer subgroup for all time-points appear in
Additional file 2. Results from multivariable analyses of
CTC number appear in Table 3.
Morphologic characteristics of CTCs in relation to CTC
counts
All investigated CTC characteristics (apoptosis, clustering,
WBC-CTCs) were significantly associated with CTC num-
ber at all time-points (P-value < 0.001; Additional file 3).
No association to tumor burden as measured by the pres-
ence of visceral metastases was confirmed between either
CTC characteristics or CTC number. At BL, a weak asso-
ciation existed between the presence of apoptotic CTCs
and WBC-CTCs (P-value = 0.011) but not for the other
investigated characteristics (Additional file 3). At 1–3 and













Age at MBC diagnosis
Median (range) 60 (40–83) 64 (40–83) 57 (45–76) 51 (42–57) 0.10
< 50 years 12 9 1 2 0.45
≥ 50 years 40 30 6 2
Time to recurrence
Median (range in years) 5.3 (0–27.6) 5.1 (0–27.6) 1.7 (0–5.3) 1.3 (1.2–2.3) 0.007
Nr of patients with stage IV at diagnosis 9 5 4 0 0.44
NHG
I 2 2 0 0 0.50
II 23 18 2 2
III 18 13 2 2
Unknown 9 6 3 0
Ki67
Low (≤20%) 5 5 0 0 0.071
High (>20%) 16 8 4 4
Unknown 31 26 3 0
First-line systemic therapy
Endocrine only 11 11 0 0 b
Chemotherapy only 35 28 1 4
HER2-directed (with chemotherapy) 6 0 6 0
Metastatic site at BL
Locoregional 3 1 0 2 0.30
Skeletal only 19 15 3 1
CNS 1 1 0 0
Visceral (two with unknown subtype) 28 21 4 1
Other locations 1 1 0 0
Number of metastatic locations
1–2 32 24 4 3 0.74
3 or more 20 15 3 1
a Breast cancer subtype was derived from the primary tumor (n = 40) and, if no primary tumor tissue was available, from the metastasis (n = 10). Two patients had
insufficient tissue for subtype assessment
b No statistical analysis was performed for this clinically descriptive variable
WBC-CTC, white blood cells associated with CTC; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; BL, base-line;
NHG, Nottingham histological grade; MBC, metastatic breast cancer; mo, months
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CTC count at BL median (range) 45 (5–668) 44 (5–668) 111 (12–311) 88 (39–253) 0.32
CTC count at 1–3 mo median (range) 4 (0–263) 4 (0–263) 0 (0–9) 87 (75–144) 0.007
CTC count at 6 mo median (range) 1 (0–765) 1 (0–765) 0 (0–183) 2 (2–2) 0.18
≥ 5 CTC at 1–3 mo 0.29
Yes 19 15 1 3
No 29 22 5 1
Missing 4 2 1 0
≥ 5 CTC at 6 mo 0.72
Yes 14 12 1 1
No 27 19 5 1
Missing 11 8 1 2
Apoptosis
Apoptotic CTC at BL 0.20
Yes 40 29 6 4
Median number (range) 5 (1–54) 3 (1–52) 6.5 (1–54) 6.5 (5–40)
Median fraction (range) 0.08 (0.01–0.33) 0.09 (0.01–0.33) 0.07 (0.04–0.17) 0.12 (0.05–0.18)
No 12 10 1 0
Missing 0 0 0 0
Apoptotic CTC 1–3 mo 0.17
Yes 17 13 1 3
Median number (range) 3 (1–18) 3 (1–18) 2 6 (3–9)
Median fraction (range) 0.13 (0.01–1.0) 0.13 (0.01–1.0) 0.22 0.04 (0.04–0.10)
No 31 24 5 0
Missing 4 2 1 1
Apoptotic CTCs 6 mo 0.49
Yes 15 12 1 2
Median number (range) 2 (1–109) 2 (1–109) 2 3 (1–5)
Median fraction (range) 0.09 (0.01–1.0) 0.11 (0.02–1.0) 0.01 0.29 (0.09–0.50)
No 26 19 5 0
Missing 11 8 1 2
Clusters
Clusters at BL 0.010
Yes 9 4 3 2
Median number (range) 2 (1–18) 3 (1–18) 4 (1–4) 1.5 (1–2)
Median fraction (range) 0.02 (0.003–0.03) 0.02 (0.003–0.03) 0.01 (0.005–0.02) 0.02 (0.02–0.03)
No 43 35 4 2
Missing 0 0 0 0
Clusters at 1–3 mo 0.026
Yes 5 3 0 2
Median number (range) 1 (1–4) 1 (1–4) 1 (1)
Median fraction (range) 0.009 (0.006–0.02) 0.009 (0.006–0.02) 0.01 (0.007–0.01)
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6 months, association among all investigated factors was
high, likely due to many samples with 0 CTCs detected
(16/48 patients at 1–3 months and 17/41 patients at
6 months; Additional file 3).
Apoptotic CTCs
CTC data appear in Table 2 and there was no difference
in the number of patients with apoptotic CTCs among
the three breast cancer subtypes at any time point
(Table 2). The median number of apoptotic CTCs
amongst patients positive for apoptosis at BL, 1–3 and 6
months were 5 (range 1–54), 3 (range 1–18) and 2
(range 1–109) respectively, and the corresponding frac-
tion of apoptotic CTCs is depicted in Table 2. PFS or OS
were not different for patients with or without apoptotic
CTCs present at BL (Table 3 and Fig. 3). In contrast, at
1–3 months, significantly shorter PFS and OS were
noted for patients with apoptotic CTCs present and
this was also true at 6 months (Table 3 and Fig. 3).
When adjusting for CTC number, breast cancer sub-
group, age at diagnosis, time to recurrence, type and
number of metastases, the presence of apoptotic
CTCs was significantly related to increased HR at 1–
3 and 6 months in terms of OS and at 1–3 months
for PFS (Table 3). The fraction of apoptotic CTCs in
relation to number of CTCs was not related to out-
come (data not shown). Landmark analysis showed
that patients with apoptotic CTCs present at any
time-point during the study had significantly poorer
PFS and OS compared to patients without apoptotic
CTC. These results were consistent also in multivari-
able analysis (Table 3).
Table 2 CTC counts and morphologic characteristics in relation to breast cancer subtypea (Continued)
No 43 34 6 1
Missing 4 2 1 1
Clusters at 6 mo 0.98
Yes 4 3 1 0
Median number (range) 6 (1–16) 10 (2–16) 1
Median fraction (range) 0.003 (0.001–0.006) 0.001 (0.001–0.005) 0.006
No 37 28 5 2
Missing 11 8 1 2
WBC-CTC
WBC-CTC at BL 0.45
Yes 35 26 6 3
Median number (range) 4 (1–38) 3 (1–38) 6.5 (1–13) 4 (2–22)
Median fraction (range) 0.05 (0.004–0.6) 0.05 (0.004–0.6) 0.07 (0.02–0.2) 0.04 (0.03–0.09)
No 17 13 1 1
Missing 0 0 0 0
WBC-CTC at 1–3 mo 0.61
Yes 12 10 0 2
Median number (range) 3.5 (1–101) 3.5 (1–28) 51.5 (2–101)
Median fraction (range) 0.1 (0.02–1) 0.1 (0.04–1) 0.4 (0.02–0.7)
No 36 27 6 1
Missing 4 2 1 1
WBC-CTC at 6 mo 0.49
Yes 8 6 1 1
Median number (range) 6 (1–62) 5.5 (1–62) 9 3
Median fraction (range) 0.05 (0.009–0.09) 0.04 (0.009–0.09) 0.05 0.05
No 33 25 5 1
Missing 11 8 1 2
WBC-CTC white blood cells associated with CTC, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, BL base-line,
NHG Nottingham histological grade, MBC metastatic breast cancer, mo months
a Breast cancer subtype was derived from the primary tumor (n = 40) and, if no primary tumor tissue was available, from the metastasis (n = 10). Two patients had
insufficient tissue for subtype assessment
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CTC clusters
Fourteen patients (27%) had CTC clusters present at any
time during the study and the median number of CTC
clusters amongst patients positive for clusters at BL, 1–3
and 6 months were 2 (range 1–18), 1 (range 1–4) and 6
(range 1–16) respectively. Detailed information on all
patients with CTC clusters appear in Additional file 4.
At BL, CTC clusters were more frequently found in blood
samples from patients with HER2-positive and triple-
negative breast cancer compared to patients with hor-
mone receptor-positive cancer (Table 2; P-value = 0.010).
At 1–3 months, CTC clusters were still more frequent in
the triple-negative breast cancer group (P-value = 0.026),
whereas no significant difference could be found at 6
months (P-value = 0.98; Table 2). The fraction of CTC
clusters in relation to CTC count is presented in Table 2.
Survival of patients with CTC clusters present at BL
was not different from patients without CTC clusters. At
1–3 months, shorter PFS and OS for patients with CTC
clusters present in the blood were recognized compared
to patients with no clusters present (Table 3 and Fig. 4).
At 6 months, clusters were associated with shorter PFS
whereas HR for OS was not defined because all patients
in the cluster-positive group died prior to a patient death
in the group without clusters (see Fig. 4 for Kaplan-
Meier curves with log-rank P-value < 0.001). Multivari-
able analysis adjusting for CTC number and other
prognostic factors, indicated increased HRs but no sig-
nificant effect on prognosis when a patient was diag-
nosed with CTC clusters at 1–3 and 6 months (Table 3).
Time-dependent landmark analysis confirmed that pa-
tients with clusters at any time during the study period
Table 3 Cox uni- and multivariable analysis by presence of apoptotic CTC, CTC clusters and WBC-CTC at base-line, 1–3 months, 6
months follow-up and by apoptotic CTC and clusters present at any time during the study (time-dependent covariates). At 1–3 and
6 months, CTC numbers categorized as ≥ 5 vs 0–4, is also presented
PFS univariable PFS multivariable OS univariable OS multivariable
BLa (N = 52) (N = 50)b (N = 52) (N = 50)b
HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value
Apoptosis 1.3 0.60–2.7 0.52 1.1 0.34–3.5 0.88 1.5 0.60–3.8 0.38 3.0 0.73–12 0.13
Cluster 0.90 0.37–2.2 0.81 0.83 0.21–3.4 0.80 1.1 0.36–3.1 0.92 0.73 0.11–4.9 0.75
WBC-CTC 1.0 0.50–2.0 0.98 0.82 0.33–2.0 0.67 0.76 0.35–1.7 0.49 0.69 0.20–2.3 0.54
1–3 months (N = 45) (N = 43)c (N = 48) (N = 46)c
HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value
≥5 CTC 4.6 2.0–11 <0.001 4.3 1.1–17 0.041 5.8 2.3–14 <0.001 34 3.1–367 <0.001
Apoptosis 4.9 2.1–11 <0.001 4.5 1.0–20 0.047 5.7 2.4–14 <0.001 10 1.2–87 0.031
Cluster 7.4 2.3–24 0.001 2.0 0.30–14 0.46 9.8 2.5–38 0.001 3.1 0.48–20 0.23
WBC-CTC 1.8 0.76–4.1 0.33 0.49 0.18–3.0 0.67 1.9 0.75–4.6 0.18 0.17 0.08–1.4 0.14
6 months (N = 32) (N = 30)c (N = 42) (N = 35)c
HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value
≥ 5 CTC 6.1 2.1–17 0.001 53 4.5–613 0.002 2.7 1.0–7.1 0.047 0.47 0.02–13 0.66
Apoptosis 4.8 1.7–13 0.003 2.1 0.34–13 0.42 6.2 2.2–18 0.001 79 5.5–1137 0.001
Cluster 13 2.2–79 0.005 3.9 0.12–124 0.44 +∞d Undefined <0.001e Not included
WBC-CTC 3.1 0.97–10 0.056 0.14 0.01–1.6 0.11 7.1 2.4–21 <0.001 23 1.1–458 0.042
Time-dependent (N = 52) (N = 50)b (N = 52) (N = 50)b
HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value
Apoptosis 5.0 2.2–11 <0.001 6.7 2.4–19 <0.001 6.4 2.6–16 <0.001 25 5.2–115 <0.001
Cluster 4.8 1.9–12 0.001 1.8 0.51–6.5 0.36 16 4.6–58 <0.001 7.0 1.7–28 0.006
WBC-CTC white blood cells associated with CTC, PFS progression free survival, OS overall survival, HR Hazard ratio calculated with Cox Regression, CI confidence interval
a At BL, only patients with ≥5 CTCs were included and this variable (≥ 5 vs 0–4) is consequently not evaluated in survival analysis at this time point
b Adjusted for: CTC number ≥20, breast cancer subgroup, age at diagnosis (continuous), time to recurrence, number (≥3 vs 1–2) and site of metastases
(categorical on 5 levels)
c Adjusted for: breast cancer subgroup, age at diagnosis, time to recurrence (continuous), number (≥3 vs 1–2) and site of metastases (categorical on 5 levels). Not
adjusted for site of metastases at 6 months due to non-converging maximum likelihood estimation procedure
d All four patients with clusters died before any of the patients in the group without clusters died (perfect prediction)
e P-value from log-rank test
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had an increased risk of cancer progression and death
compared to patients who never had CTC clusters
(Table 3). The increased risk was also retained for OS in
multivariable analysis (Table 3). In line with the inferior
prognosis in patients with presence of CTC clusters in
FU samples, patients with increasing fraction of CTC
clusters per CTC number in FU samples had impaired
prognosis (1–3 months: HRPFS = 6.7, 95 % CI 2.4–18.7,
P < 0.001; HROS = 12.1, 95 % CI 3.40–43.19, P < 0.001).
The fraction of CTC clusters in 6 months FU samples
was also significantly correlated to worse outcome,
but due to the smaller sample size the results are
uncertain.
WBC-CTCs
Table 2 depicts patient WBC-CTC data and WBC-CTC
presence did not differ among the three breast cancer
subgroups at BL or at 1–3 or 6 months. The median
number of WBC-CTC amongst patients positive for
WBC-CTC at BL, 1–3 and 6 months were 4 (range 1–
38), 3.5 (range 1–101) and 6 (range 1–62) respectively
and the corresponding fraction of WBC-CTC is dis-
played in Table 2. No significant difference in survival
was observed for patients with WBC-CTCs present at
BL or 1–3 months compared to patients with no WBC-
CTCs. However, at 6 months, worse survival in terms of
PFS and OS was observed for patients with WBC-CTC
Fig. 3 Kaplan-Meier survival plots and log-rank test by presence of apoptosis. Results from Cox-analyses are included in the respective graph. PFS
and OS for patients with apoptotic CTCs present vs absent at BL, 1–3 and 6 months
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(Table 3 and Additional file 5). In contrast, multivariable
analysis indicated that the presence of WBC-CTC had a
positive effect on survival for both PFS and OS at 1–3
months and on PFS at 6 months, but these results were
not significant (Table 3). At 6 months the presence of
WBC-CTC was significantly related to worse OS in mul-
tivariable analysis (Table 3). The fraction of WBC-CTC
per number of CTC did not add any prognostic informa-
tion (data not shown).
Discussion
The prognostic information of CTC enumeration in FU
blood samples has been shown in a number of studies
[1, 6–9] but the added value of CTC characterization in
FU samples is largely unknown. Apoptotic CTCs and
CTC clusters in metastatic breast cancer has gained
recent attention and in the present exploratory study
we investigated the significance of these morphologic
characteristics using the CellSearch gallery in a
homogenous cohort from patients with poor progno-
sis (≥5 CTCs at base-line (BL)) metastatic breast can-
cer undergoing first-line systemic therapy including
all breast cancer subtypes. We show that the presence
of apoptotic CTCs and CTC clusters in FU blood
samples at 1–3 and 6 months after treatment initiation in-
dicated poorer prognosis. Moreover, Cox-models with
Fig. 4 Kaplan-Meier survival plots and log-rank test by presence of CTC clusters. Results from Cox-analyses are included in the respective graph
PFS and OS for patients with CTC clusters present vs absent at BL, 1–3 and 6 months
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time-dependent covariates confirmed that the presence of
apoptotic CTCs and CTC clusters at any time-point dur-
ing the study was associated with increased mortality
independent of other prognostic factors such as CTC
numbers and breast cancer subtype.
Our findings agree with a recent study of metastatic
triple-negative breast cancer in which presence of CTC
clusters diagnosed using the CellSearch gallery in FU
blood samples during the first month of treatment was
associated to significantly worse PFS [12]. However, we
included patients with all subtypes of breast cancer with
CTC number ≥5 at BL and limited inclusion of patients
to those about to start first-line systemic therapy, thus
the prognostic information yielded by morphologic char-
acteristics is not only related to pretreated patients or
any specific subtype of breast cancer. Another recent
publication has also suggested that detection of CTC
clusters is important when evaluating prognosis in
breast cancer [14]. Both publications [12, 14] used
the CellSearch system for CTC enumeration and
characterization, but applied separate definitions for
CTC clusters. In the study by Mu et al. [14], includ-
ing patients with breast cancer stage III and IV, the
presence of CTC clusters (defined as ≥2 CTCs) at BL
was associated to worse prognosis in terms of de-
creased PFS. A majority of patients (69 out of 115) in
this study had inflammatory breast cancer and the au-
thors conclude that these patients had larger clusters;
five of seven patients in this study with CTC clusters
of ≥3 CTCs had inflammatory breast cancer. The
publication by Paoletti et al. [12] investigated the im-
portance of CTC clusters and apoptosis in metastatic
triple-negative breast cancer. They found that CTC
clusters (defined as ≥3 CTCs) but not apoptotic CTCs
(defined by any M-30 staining and/or visual charac-
teristics of apoptosis) in FU blood samples during
treatment was associated with worse PFS.
In the present study retained CTC clusters added sig-
nificant prognostic information after 1–3 and 6 months
of first line therapy. Also, clusters were found signifi-
cantly more often in patients with triple-negative breast
cancer compared to hormone receptor-positive cancer.
Previous studies indicate that CTCs within clusters may
represent a more malignant and mesenchymal subpopu-
lation of tumor cells [20, 28]. Early experiments in ani-
mal models indicate that intravenously injected tumor
cell clusters have a greater tendency to form metastases
than an equal number of injected single CTCs [39, 40].
Adding to these findings, Aceto et al. recently reported
that CTC clusters in breast cancer have a 23- to 50-fold
increased metastatic potential [20]. Furthermore, no
apoptotic CTCs were found within CTC clusters in the
blood of patients with lung cancer, suggesting that
tumor cells in clusters have a survival advantage
compared to solitary CTC [13]. We confirm these re-
sults in breast cancer, as no apoptotic CTCs were found
in cell clusters in our patients. Likely, clustered CTCs
evade anoikis by retaining cell-to-cell survival signals
by expressing proteins responsible for intracellular
junctions, exemplified by plakoglobin [20]. Moreover,
characterization of CTCs within clusters supports the
hypothesis that CTCs within clusters are different
from single CTC—they are non-proliferating as indi-
cated by the absence of Ki67 expression [4].
In this cohort of patients with metastatic breast cancer,
we found no apoptotic CTCs within clusters, but all pa-
tients with clusters also had apoptotic single CTCs. The
presence of apoptotic CTCs was also related to poor
outcome at 1–3 and 6 months, whereas no association
to prognosis could be seen at BL. Persistent apoptotic
CTCs over time indicates a failure to respond to sys-
temic therapy with retained proliferation and cell turn-
over in the metastatic lesion and/or primary tumor [4].
This could be a possible explanation for the dismal prog-
nosis for patients with retained apoptotic CTCs during
treatment as found in the present study. Our results are
not consistent with previous studies using CellSearch for
detection and analysis of apoptotic CTCs [4, 12]. In con-
trast to our data, Hou et al. found that presence of ≥1
apoptotic CTC at BL was associated with significantly
worse PFS and OS in lung cancer [4] (the study did not
analyze apoptotic CTCs in FU samples). On the other
hand, in metastatic triple-negative breast cancer, Paoletti
et al. found no prognostic effect of apoptotic CTCs
either at BL or in FU samples at day 15 and 29 [12].
Our data suggest that samples taken after several cy-
cles of systemic treatment have a higher significance
for prognostic information. In contrast to the studies
above, we included no further staining (e.g. M30)
after CellSearch analysis and only used morphological
criteria for diagnosis of apoptotic CTCs. It is possible
that early stage apoptotic CTCs, as detected by add-
itional staining, carry less prognostic information. Also,
we found no evidence for prognostic significance by
analyzing the fraction of apoptotic CTCs as applied by
Paoletti et al. [12].
The prognostic importance of WBC-CTCs in patients
with metastatic breast cancer has, to our knowledge, not
been previously investigated. Interestingly, univariable
analysis in this cohort indicated worse prognosis for pa-
tients with WBC-CTCs present whereas adjustment for
other prognostic factors such as CTC number, age, and
time to recurrence lowered HR to less than 1, suggesting
that WBC-CTCs could be favorable for survival. Possibly
further characterization of CTC-associated leukocytes
may provide prognostic information [41], but the
CellSearch methodology only specifies leukocyte pres-
ence by the phenotype CK-/CD45+/DAPI+. Thus, no
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detailed information on leukocyte types associated with
CTC is available within the present study.
As enumeration of CTCs was prognostic in the pre-
sented cohort and we found an association between
CTC number and all morphologic characteristics, we
also accounted for the fraction of CTCs with the re-
spective morphological characteristic in relation to the
total CTC count in each patient. The fraction of CTC
clusters added prognostic information in FU samples,
supporting that CTC clusters add important prognostic
information to enumeration of CTCs. The fraction of
apoptotic CTCs and WBC-CTCs was not significantly
related to prognosis in contrast to the presence of the
respective morphological trait.
A limitation of the study is that we included only 52
patients with metastatic breast cancer in this exploratory
analysis and the statistical power was consequently lim-
ited. Although we selected patients based on cut-point
for CTC enumeration, the median CTC count at BL was
45 for all included patients as an indication of a group
of patients with dismal prognosis. Another limitation of
the study is that patients within triple-negative and
HER2-positive subgroups were underrepresented but di-
agnosed significantly more often with CTC clusters at
BL. Four patients with HER2-positive subtype were in-
cluded, three of which cleared their CTCs after 6
months of FU and one with progressive disease after 5
months (Additional file 4). The patient with disease pro-
gression had increased number of CTCs and also pre-
sented with clusters at 6 months. The most efficient
eradication of CTCs and CTC clusters occurred in a pa-
tient treated with HER2-directed double blockade diag-
nosed with 311 CTC at BL and four clusters. The
finding indicates that dynamic changes of CTCs evolving
under the pressure of systemic therapy may be predictive
for treatment success. In contrast, all patients in the dif-
ficult to treat triple-negative subgroup (N= 4) had a con-
stant presence of apoptotic CTCs during the study
(Table 2), both at BL and during chemotherapy. A
higher cell turn-over rate in patients with triple-negative
subtype may be one explanation for the dismal prognosis
in this breast cancer subtype.
This exploratory study was performed by evaluating
CTCs captured with the FDA approved CellSearch
system without any downstream staining and our
study can be repeated in more patients in clinical
studies using CTCs as surrogate marker. CTC apop-
tosis, clusters and WBC-CTCs were assessed morpho-
logically directly in the CellSearch gallery following
assessment guidelines proposed in previous publica-
tions. Even if the CTC galleries provided by the
CellTracks Analyzer II system only offers pictures
with 10 x magnifications, CellSearch is the most used
and well documented CTC isolation system available.
Thus, being able to extract putative prognostic informa-
tion by including basic and easy-to-assess morphologic
characteristics in addition to today’s enumeration, an even
more powerful prognostic tool may lie ahead for patients
presenting with ≥5 CTC/7.5 ml blood at BL. Confirmation
that apoptotic CTCs and CTC clusters observed in Cell-
Search analyses are not a result of artifacts but indeed true
morphologic characteristics have been presented previ-
ously [4, 12, 42]. We applied a published definition of a
CTC cluster to enable comparison with previous studies
[12, 13] and the definition of apoptosis was according to
criteria used in clinical pathology [13, 36] without the
need of further staining after CellSearch analysis. Further
validation of morphological assessment of CTCs in inde-
pendent and larger cohorts is warranted.
Conclusions
The clinical value of monitoring CTC counts in meta-
static breast cancer has recently been confirmed in a
large meta-analysis [1]. Morphologic characterization
of CTCs by assessment of apoptotic CTCs and CTC
clusters may offer additional prognostic information
to enumeration in patients with ≥5 CTC/7.5 ml blood
at BL.In the present study, we evaluated apoptotic
CTCs, CTC clusters and WBC-CTCs in patients with
poor prognosis metastatic breast cancer using the
standardized CTC capture and presentation system
from Janssen Diagnostics, the CellSearch system. Ser-
ial sampling from patients treated systemically with
first-line approaches was performed from therapy ini-
tiation to 6 months. We observed significantly worse
prognosis for patients with apoptotic CTCs and CTC
clusters present in peripheral blood during treatment,
suggesting that morphologic characterization of per-
sistent CTCs during treatment may be an important
prognostic marker, in addition to CTC enumeration
alone.
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